Membranous Nephropathy
37
12
14
13
Key Insights
Highlights
Success Rate
81% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 52/100
8.1%
3 terminated out of 37 trials
81.3%
-5.3% vs benchmark
11%
4 trials in Phase 3/4
23%
3 of 13 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 13 completed trials
Clinical Trials (37)
NEPTUNE Match Study
A Clinical Study Evaluating the Safety and Efficacy of GT719 Universal Cell Injection in the Treatment of Immune-mediated Kidney Diseases
Efficacy and Safety of CD19 CAR-γδ T Cells in the Treatment of Relapsed/Refractory Autoimmune Nephropathy
Role of Anti-mouse PLA2R1 ELISA in Membranous Nephropathy
An Outcome Analysis of Primary Membranous Nephropathy
Effect of B-cell Depleting Therapies on PLA2R-specific B Cells in Patients With Membranous Nephropathy
Autoreactive B Cells in Membranous Nephropathy
Analysis of T- and B-Cell Subpopulations in Membranous Nephropathy
Omics of Rituximab-resistance
Belimumab With Rituximab for Primary Membranous Nephropathy
Efficacy and Safety of VB119 in Subjects With Membranous Nephropathy
Interview Study of Adult and Child Patients and Parents of Children With Swelling Due to Nephrotic Syndrome.
A Study to Evaluate the Efficacy, Safety, and Tolerability of Human Sialidase Fusion Protein (HLX79) in Combination With Rituximab Injection Versus Placebo in Patients With Active Glomerulonephritis
An Open-label Study of Povetacicept in Autoantibody-Associated Glomerular Diseases
Personalized Rituximab Treatment Based on Artificial Intelligence in Membranous Nephropathy (iRITUX)
Obinutuzumab in Primary MN
Nephrotic Syndrome Study Network
MOR202 for Refractory MN
Phase II Study Assessing Safety and Efficacy of APL-2 in Glomerulopathies
Efficacy, Safety and PK/PD of MOR202 in Anti-PLA2R+ Membranous Nephropathy (aMN) (NewPLACE)